Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program
Date
2022
Authors
Keir, A.
Rumbold, A.
Shepherd, E.
Mcintyre, S.
Groves, C.
Cavallaro, A.
Crowther, C.
Callander, E.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Australian and New Zealand Journal of Obstetrics and Gynaecology, 2022; 62(1):168-171
Statement of Responsibility
Amy Keir, Alice Rumbold, Emily Shepherd, Sarah Mcintyre, Charlotte Groves, Angela Cavallaro, Caroline Crowther, and Emily Callander
Conference Name
Abstract
Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
School/Discipline
Dissertation Note
Provenance
Description
First published: 29 November 2021
Access Status
Rights
© 2021 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists